At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Closed 05-17 16:00:00 EDT
2.47
+0.22
+9.78%
盘后2.47
+0.000.00%
19:51 EDT
High2.47
Low2.25
Vol96.72K
Open2.35
D1 Closing2.25
Amplitude9.98%
Mkt Cap65.22M
Tradable Cap34.82M
Total Shares26.40M
T/O232.23K
T/O Rate0.69%
Tradable Shares14.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Immix Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.